

Brett Lauring

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7027882/publications.pdf>

Version: 2024-02-01

15
papers

1,118
citations

758635

12
h-index

996533

15
g-index

15
all docs

15
docs citations

15
times ranked

762
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1474-1482. | 2.2 | 38 |
| 2 | Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Current Medical Research and Opinion</i> , 2019, 35, 1335-1343. | 0.9 | 32 |
| 3 | Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1027-1036. | 2.2 | 48 |
| 4 | Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. <i>Diabetes Therapy</i> , 2018, 9, 253-268. | 1.2 | 68 |
| 5 | Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1453-1460. | 2.2 | 70 |
| 6 | Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1111-1120. | 2.2 | 121 |
| 7 | Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. <i>Diabetes Therapy</i> , 2018, 9, 193-207. | 1.2 | 86 |
| 8 | Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 520-529. | 2.2 | 136 |
| 9 | Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 530-540. | 2.2 | 121 |
| 10 | Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. <i>Diabetes Therapy</i> , 2018, 9, 49-66. | 1.2 | 99 |
| 11 | Design and baseline characteristics of the eValuation of Ertugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23. | 1.2 | 171 |
| 12 | Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. <i>Diabetes</i> , 2018, 67, 1145-P. | 0.3 | 3 |
| 13 | Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 721-728. | 2.2 | 113 |
| 14 | Single therapeutic and suprathreshold doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 765-775. | 1.0 | 4 |
| 15 | Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1247-1255. | 1.0 | 8 |